We are delighted to announce the first Global Virtual Symposium on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD 2025), scheduled for December 8–9, 2025, organized by Scirease. This landmark event will bring together distinguished experts from around the world to explore the latest research, clinical advancements, and innovations in the study of MASLD.

MASLD, formerly known as nonalcoholic fatty liver disease (NAFLD), is now recognized as one of the most prevalent chronic liver conditions globally, affecting over 30% of the population. It is a multifaceted disorder driven by complex interactions among cardiometabolic and environmental risk factors. The progressive form of MASLD, previously termed nonalcoholic steatohepatitis (NASH), has been redefined as metabolic dysfunction-associated steatohepatitis (MASH). First described in 1980, MASH mimics the histological features of alcohol-related liver disease in individuals without significant alcohol intake or other liver conditions. The global surge in MASLD prevalence has sparked intense research into its pathophysiology, clinical implications, and socioeconomic impact.

This virtual symposium will enable participants to engage from anywhere in the world, fostering global collaboration and the exchange of cutting-edge knowledge. The program will feature presentations from leading experts in liver disease, who will share pioneering research, clinical insights, and therapeutic innovations.

We invite researchers, clinicians, and professionals with an interest in liver health to contribute to our collective efforts in understanding, preventing, and treating MASLD and MASH.

We look forward to your participation and eagerly anticipate welcoming you to MASLD 2025 this December.